18
June 2020

Mutagenic impurity risk evaluation – technologies to assist in stepwise approach to assessment

Location:

Free to attend webinar

We are proudly sponsoring the mutagenic impurity risk evaluation webinar.

This free to attend webinar will look to present an overview of a systematic approach to the conduct of a mutagenic impurity risk assessment and examine how to align this to the requirements of ICH M7. At each step in the process it will look to provide examples of the technology that is available to enable a consistent and thorough approach, looking at aspects such as in silico assessment, control options and the use of purge calculations, instrument technology, sample preparation and service providers. It will also examine the future of ICH M7 and reflect on recent challenges associated with N-Nitrosamines and their current and future impact.

This webinar will be presented by Dr Andrew Teasdale, AstraZeneca. Andrew is the author of the ICH Quality Guidelines: An Implementation Guide  and tutor on the 2-day course: Practical management of impurities and development of effective and comprehensive control strategies.

The webinar will last for approximately 90 minutes and starts at the following time:

3.00 pm UK
4.00 pm Central Europe
10.00 am East Coast US

For more information, or to register please visit: Mutaganic impurity webinar